---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-025569"
form_type: "8-K"
ticker: "ETON"
cik: "0001710340"
company_name: "Eton Pharmaceuticals, Inc."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T11:03:40.956740+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Eton Q2 product sales up 40% YoY to $9.1M; ET-400 NDA accepted with Feb 2025 PDUFA

## Summary
- Product sales and royalty revenue $9.1M, up 40% YoY and 14% sequentially; 14th straight quarter of sequential growth.
- Net loss of $2.9M ($0.11/share) including $2.0M ET-400 filing fee; prior year net income $4.6M included $5.5M royalty sale.
- ALKINDI SPRINKLE revenue grew 63% YoY; Carglumic Acid sales continue to exceed expectations.
- NDA for ET-400 (hydrocortisone oral solution) accepted with PDUFA date Feb 28, 2025; launch quantities planned Q4 2024.
- Cash $17.7M; generated $1.3M operating cash flow in Q2; expects positive cash flow for remainder of 2024.

## SEC filing metadata
- accession: 0001437749-24-025569
- form_type: 8-K
- ticker: ETON
- cik: 0001710340
- company_name: Eton Pharmaceuticals, Inc.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1710340/000143774924025569/0001437749-24-025569-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1710340/000143774924025569/eton20240802_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-025569
- JSON: https://secwatch.observer/filing/0001437749-24-025569.json
- Plain text: https://secwatch.observer/filing/0001437749-24-025569.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.